By: David Shifrin, PhD Life Science Consultant and Freelance Writer Last December, in front of several thousand scientists, J. Craig Venter delivered the keynote address at the annual American Society for Cell Biology (ASCB) meeting in San Francisco. Venter is, to state the obvious, a controversial figure in scientific circles, but his vision for the… Read More A look at the future of genetics and human disease
By: David Shifrin, PhD Life Science Consultant and Freelance Writer Throughout the last 25 years, the molecular revolution has provided scientists and clinicians with a rapidly expanding toolbox for both analyzing and manipulating biological systems at the level of single amino and nucleic acids. Techniques to induce individual mutations or remove entire genes have become… Read More CRISPR: treating the genetic underpinnings of disease with a bacterial “immune system”?
Last week, the FDA submitted a 60-day notification to Congress of its intent to publish a draft guidance of a risk-based framework for regulating Laboratory Developed Tests, or LDT’s. This information, while still young and being adsorbed by the industry will represent a major shift in how molecular diagnostics are regulated for clinical use. Since… Read More The Genetic Testing Market and Proposed FDA LDT Regulations
By: David Shifrin, PhDLife Science Consultant and Freelance Writer With the announcement of the new Google X project Baseline, reported in the Wall Street Journal last week, the idea of “big data” is once again at the front of the news. To be fair, big data hadn’t really gone anywhere, but Google’s latest project… Read More Another step forward for Big Data